Picture loading failed.

Anti-CD37 therapeutic antibody (Pre-made Otlertuzumab biosimilar,di-scFv+Fc) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Otlertuzumab (TRU-016) is a humanized monoclonal antibody that targets CD37 designed for the treatment of cancer.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-416-1mg 1mg Inquiry
GMP-Bios-ab-416-10mg 10mg Inquiry
GMP-Bios-ab-416-100mg 100mg Inquiry
GMP-Bios-ab-416-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-CD37 therapeutic antibody (Pre-made Otlertuzumab biosimilar,di-scFv+Fc)
INN Name Otlertuzumab
TargetCD37
Formatdi-scFv+Fc
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2013
Year Recommended2014
CompaniesTrubion Pharmaceuticals;Aptevo Therapeutics
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedChronic lymphocytic leukaemia;Non-Hodgkin's lymphoma;Peripheral T-cell lymphoma
Development TechADAPTIR Monospecific Platform